301 related articles for article (PubMed ID: 23906020)
1. The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia.
Stankovic T; Skowronska A
Leuk Lymphoma; 2014 Jun; 55(6):1227-39. PubMed ID: 23906020
[TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition.
Quijada-Álamo M; Hernández-Sánchez M; Alonso-Pérez V; Rodríguez-Vicente AE; García-Tuñón I; Martín-Izquierdo M; Hernández-Sánchez JM; Herrero AB; Bastida JM; San Segundo L; Gruber M; García JL; Yin S; Ten Hacken E; Benito R; Ordóñez JL; Wu CJ; Hernández-Rivas JM
Leukemia; 2020 Jun; 34(6):1599-1612. PubMed ID: 31974435
[TBL] [Abstract][Full Text] [Related]
3. Biallelic ATM alterations detected at diagnosis identify a subset of treatment-naïve chronic lymphocytic leukemia patients with reduced overall survival similar to patients with p53 deletion.
Lozano-Santos C; García-Vela JA; Pérez-Sanz N; Nova-Gurumeta S; Fernandez-Cuevas B; Gomez-Lozano N; Sánchez-Beato M; Sanchez-Godoy P; Bueno JL; Garcia-Marco JA
Leuk Lymphoma; 2017 Apr; 58(4):859-865. PubMed ID: 27499002
[TBL] [Abstract][Full Text] [Related]
4. Dissecting the role of TP53 alterations in del(11q) chronic lymphocytic leukemia.
Quijada-Álamo M; Pérez-Carretero C; Hernández-Sánchez M; Rodríguez-Vicente AE; Herrero AB; Hernández-Sánchez JM; Martín-Izquierdo M; Santos-Mínguez S; Del Rey M; González T; Rubio-Martínez A; García de Coca A; Dávila-Valls J; Hernández-Rivas JÁ; Parker H; Strefford JC; Benito R; Ordóñez JL; Hernández-Rivas JM
Clin Transl Med; 2021 Feb; 11(2):e304. PubMed ID: 33634999
[TBL] [Abstract][Full Text] [Related]
5. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion.
Austen B; Skowronska A; Baker C; Powell JE; Gardiner A; Oscier D; Majid A; Dyer M; Siebert R; Taylor AM; Moss PA; Stankovic T
J Clin Oncol; 2007 Dec; 25(34):5448-57. PubMed ID: 17968022
[TBL] [Abstract][Full Text] [Related]
6. Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia.
Knittel G; Rehkämper T; Korovkina D; Liedgens P; Fritz C; Torgovnick A; Al-Baldawi Y; Al-Maarri M; Cun Y; Fedorchenko O; Riabinska A; Beleggia F; Nguyen PH; Wunderlich FT; Ortmann M; Montesinos-Rongen M; Tausch E; Stilgenbauer S; P Frenzel L; Herling M; Herling C; Bahlo J; Hallek M; Peifer M; Buettner R; Persigehl T; Reinhardt HC
Nat Commun; 2017 Jul; 8(1):153. PubMed ID: 28751718
[TBL] [Abstract][Full Text] [Related]
7. Late appearance of the 11q22.3-23.1 deletion involving the ATM locus in B-cell chronic lymphocytic leukemia and related disorders. Clinico-biological significance.
Cuneo A; Bigoni R; Rigolin GM; Roberti MG; Bardi A; Cavazzini F; Milani R; Minotto C; Tieghi A; Della Porta M; Agostini P; Tammiso E; Negrini M; Castoldi G
Haematologica; 2002 Jan; 87(1):44-51. PubMed ID: 11801464
[TBL] [Abstract][Full Text] [Related]
8. Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial.
Skowronska A; Parker A; Ahmed G; Oldreive C; Davis Z; Richards S; Dyer M; Matutes E; Gonzalez D; Taylor AM; Moss P; Thomas P; Oscier D; Stankovic T
J Clin Oncol; 2012 Dec; 30(36):4524-32. PubMed ID: 23091097
[TBL] [Abstract][Full Text] [Related]
9. ATM function and its relationship with ATM gene mutations in chronic lymphocytic leukemia with the recurrent deletion (11q22.3-23.2).
Jiang Y; Chen HC; Su X; Thompson PA; Liu X; Do KA; Wierda W; Keating MJ; Plunkett W
Blood Cancer J; 2016 Sep; 6(9):e465. PubMed ID: 27588518
[TBL] [Abstract][Full Text] [Related]
10. ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial.
Rose-Zerilli MJ; Forster J; Parker H; Parker A; Rodríguez AE; Chaplin T; Gardiner A; Steele AJ; Collins A; Young BD; Skowronska A; Catovsky D; Stankovic T; Oscier DG; Strefford JC
Haematologica; 2014 Apr; 99(4):736-42. PubMed ID: 24584352
[TBL] [Abstract][Full Text] [Related]
11. ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin.
Navrkalova V; Sebejova L; Zemanova J; Kminkova J; Kubesova B; Malcikova J; Mraz M; Smardova J; Pavlova S; Doubek M; Brychtova Y; Potesil D; Nemethova V; Mayer J; Pospisilova S; Trbusek M
Haematologica; 2013 Jul; 98(7):1124-31. PubMed ID: 23585524
[TBL] [Abstract][Full Text] [Related]
12. ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but influences rapid disease progression through loss of the remaining ATM allele.
Skowronska A; Austen B; Powell JE; Weston V; Oscier DG; Dyer MJ; Matutes E; Pratt G; Fegan C; Moss P; Taylor MA; Stankovic T
Haematologica; 2012 Jan; 97(1):142-6. PubMed ID: 21933854
[TBL] [Abstract][Full Text] [Related]
13. Patients with chronic lymphocytic leukaemia and clonal deletion of both 17p13.1 and 11q22.3 have a very poor prognosis.
Greipp PT; Smoley SA; Viswanatha DS; Frederick LS; Rabe KG; Sharma RG; Slager SL; Van Dyke DL; Shanafelt TD; Tschumper RC; Zent CS
Br J Haematol; 2013 Nov; 163(3):326-33. PubMed ID: 24032430
[TBL] [Abstract][Full Text] [Related]
14. Cryptic deletion involving the ATM locus at 11q22.3 approximately q23.1 in B-cell chronic lymphocytic leukemia and related disorders.
Eclache V; Caulet-Maugendre S; Poirel HA; Djemai M; Robert J; Lejeune F; Raphaël M
Cancer Genet Cytogenet; 2004 Jul; 152(1):72-6. PubMed ID: 15193446
[TBL] [Abstract][Full Text] [Related]
15. Increased transferrin receptor expression following 11q23 deletion as a mechanism of malignant progression in chronic lymphocytic leukemia.
Shackelford RE; Bhalodia AR; Cotelingam JD; Veillon DM; Lowery-Nordberg M
Med Hypotheses; 2006; 66(3):509-12. PubMed ID: 16326028
[TBL] [Abstract][Full Text] [Related]
16. Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia.
Schaffner C; Stilgenbauer S; Rappold GA; Döhner H; Lichter P
Blood; 1999 Jul; 94(2):748-53. PubMed ID: 10397742
[TBL] [Abstract][Full Text] [Related]
17. Incidence and clinical implications of ATM aberrations in chronic lymphocytic leukemia.
Ouillette P; Li J; Shaknovich R; Li Y; Melnick A; Shedden K; Malek SN
Genes Chromosomes Cancer; 2012 Dec; 51(12):1125-32. PubMed ID: 22952040
[TBL] [Abstract][Full Text] [Related]
18. ATM mutations in sporadic lymphoid tumours.
Stankovic T; Stewart GS; Byrd P; Fegan C; Moss PA; Taylor AM
Leuk Lymphoma; 2002 Aug; 43(8):1563-71. PubMed ID: 12400598
[TBL] [Abstract][Full Text] [Related]
19. ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells.
Kwok M; Davies N; Agathanggelou A; Smith E; Oldreive C; Petermann E; Stewart G; Brown J; Lau A; Pratt G; Parry H; Taylor M; Moss P; Hillmen P; Stankovic T
Blood; 2016 Feb; 127(5):582-95. PubMed ID: 26563132
[TBL] [Abstract][Full Text] [Related]
20. ATM mutations in B-cell chronic lymphocytic leukemia.
Bullrich F; Rasio D; Kitada S; Starostik P; Kipps T; Keating M; Albitar M; Reed JC; Croce CM
Cancer Res; 1999 Jan; 59(1):24-7. PubMed ID: 9892178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
